These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10981107)

  • 1. Compliance, quality of life, and cost effectiveness.
    Stason WB
    Curr Hypertens Rep; 1999 Dec; 1(6):471-4. PubMed ID: 10981107
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of hypertension treatment.
    Ménard J
    Clin Exp Hypertens; 1996; 18(3-4):399-413. PubMed ID: 8743030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension and current issues in compliance and patient outcomes.
    Zyczynski TM; Coyne KS
    Curr Hypertens Rep; 2000 Dec; 2(6):510-4. PubMed ID: 11062595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness issues in hypertension control.
    Schueler K
    Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities to improve the cost-effectiveness of treatment for hypertension.
    Prichard BN
    Pharmacoeconomics; 1992 Mar; 1(3):219-21. PubMed ID: 10147110
    [No Abstract]   [Full Text] [Related]  

  • 6. Approach to polypharmacy.
    Solomon GL
    J Am Board Fam Pract; 1998; 11(4):331-2. PubMed ID: 9719359
    [No Abstract]   [Full Text] [Related]  

  • 7. [Medical economics of antihypertensive agents].
    Yamazaki T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():285-8. PubMed ID: 16981557
    [No Abstract]   [Full Text] [Related]  

  • 8. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance?
    Mar J; Rodríguez-Artalejo F
    J Hypertens; 2001 Jan; 19(1):149-55. PubMed ID: 11204296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncompliance with antihypertensive therapy. Economic consequences.
    Skaer TL; Sclar DA; Robison LM
    Pharmacoeconomics; 1996 Jan; 9(1):1-4. PubMed ID: 10160083
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of hypertension 1996. Effectiveness, tolerance, cost-benefit aspects].
    Rahn KH
    Med Klin (Munich); 1996 Jun; 91(6):380-3. PubMed ID: 8767312
    [No Abstract]   [Full Text] [Related]  

  • 11. Utility of a transdermal delivery system for antihypertensive therapy. Part 2.
    Sclar DA; Skaer TL; Chin A; Okamoto MP; Gill MA
    Am J Med; 1991 Jul; 91(1A):57S-60S. PubMed ID: 1907802
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance with antihypertensive therapy: raising the bar of expectations.
    Rudd P
    Am J Manag Care; 1998 Jul; 4(7):957-66. PubMed ID: 10181995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is cost-effectiveness analysis?
    Evans DB
    Med J Aust; 1990 Aug; 153(S1):S7-9. PubMed ID: 2116585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic issues in antihypertensive therapy.
    Giles TD
    Am J Cardiol; 1999 Jul; 84(2A):25K-28K. PubMed ID: 10437741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medical economics of hypertension therapy].
    Yamazaki T
    Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
    [No Abstract]   [Full Text] [Related]  

  • 17. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
    van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
    Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of losartan in cost-effective hypertension control.
    McIntyre H; Costa FV; Düsing R; Ambrosioni E; Gerth W
    Curr Med Res Opin; 2002; 18(3):139-45. PubMed ID: 12094823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive treatment - navigating between cost, compliance and complications.
    Conen D
    Swiss Med Wkly; 2013; 143():w13857. PubMed ID: 24163056
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.